-
公开(公告)号：US20200024344A1
公开(公告)日：2020-01-23
申请号：US16435166
申请日：2019-06-07
申请人： argenx BVBA
发明人： Hans de Haard , Peter Ulrichts , Thierry Cousin , Nicolas Leupin , Torsten Dreier , Tonke Van Bragt
摘要： A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists.
-
公开(公告)号：US20210324061A1
公开(公告)日：2021-10-21
申请号：US17096931
申请日：2020-11-12
发明人： Sebastian van der Woning , Filip Borgions , Torsten Dreier , Lore Mariën , Gitte De Boeck , Stéphanie Liénart , Sophie Lucas , Pierre Coulie
摘要： The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
-
公开(公告)号：US20180327487A1
公开(公告)日：2018-11-15
申请号：US15977449
申请日：2018-05-11
申请人： argenx BVBA
发明人： Sebastian Van der Woning , Filip Borgions , Torsten Dreier , Lore Mariën , Federica Linty , Gitte De Boeck , Hans De Haard , Stéphanie Liénart , Sophie Lucas , Pierre Coulie , Michael Saunders
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/28 , C07K2317/22 , C07K2317/32 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
-
公开(公告)号：US11117959B2
公开(公告)日：2021-09-14
申请号：US16239321
申请日：2019-01-03
申请人： argenx BVBA
发明人： Christophe Blanchetot , Johannes De Haard , Torsten Dreier , Natalie De Jonge , Sebastian Paul Van Der Woning , Nicolas Ongenae
IPC分类号： C07K16/24 , A61K39/395 , A61K39/00
摘要： The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).
-
公开(公告)号：US20200095311A1
公开(公告)日：2020-03-26
申请号：US16698833
申请日：2019-11-27
发明人： Sebastian van der Woning , Filip Borgions , Torsten Dreier , Lore Mariën , Gitte De Boeck , Stéphanie Liénart , Sophie Lucas , Pierre Coulie
摘要： The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
-
公开(公告)号：US10676535B2
公开(公告)日：2020-06-09
申请号：US15854312
申请日：2017-12-26
申请人： argenx BVBA
发明人： Anna Hultberg , Michael Saunders , Johannes De Haard , Els Festjens , Natalie De Jonge , Paolo Michieli , Cristina Basilico , Torsten Dreier
摘要： The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
-
公开(公告)号：US10479829B2
公开(公告)日：2019-11-19
申请号：US15977449
申请日：2018-05-11
发明人： Sebastian Van der Woning , Filip Borgions , Torsten Dreier , Lore Mariën , Gitte De Boeck , Stéphanie Liénart , Sophie Lucas , Pierre Coulie
摘要： The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
-
公开(公告)号：US20190270823A1
公开(公告)日：2019-09-05
申请号：US16278522
申请日：2019-02-18
申请人： argenx BVBA
发明人： Karen Silence , Peter Ulrichts , Johannes Joseph Wilhelmus De Haard , Torsten Dreier , Michael John Scott Saunders , Harald Wajant , Sofie Maria Elvire Gabriels , Mahan Moshir
IPC分类号： C07K16/28
摘要： The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
-
公开(公告)号：US20190194277A1
公开(公告)日：2019-06-27
申请号：US16213422
申请日：2018-12-07
申请人： argenx BVBA
CPC分类号： C07K14/4703 , A61K9/0019 , A61K38/00 , A61K45/06 , A61P37/00 , C07K16/00 , C07K2317/52 , C07K2317/526 , C07K2317/92 , C07K2317/94
摘要： Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.
-
公开(公告)号：US10316073B2
公开(公告)日：2019-06-11
申请号：US14580771
申请日：2014-12-23
发明人： Peter Ulrichts , Christophe Blanchetot , Torsten Dreier , Johannes de Haard , E. Sally Ward Ober , Nicolas G. H. Ongenae
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.026 秒)
